Multiplo 5 Weeks

Adult administration

Use as prescribed by a physician, adjusting dosage based on plasma trace element levels. Patients receiving metabolism-stable non-oral nutritional solutions: Zinc 2.5 to 4 mg per day Copper 0.5 to 1.5 mg per day Manganese 0.15 to 0.8 mg per day Chromium 10 to 15 μg per day Selenium 20 to 40 μg per day Patients in acute inflammatory states: 4.5 to 6 mg per day Patients with metabolism-stable small bowel fluid losses: 20 μg per day.

Child administration

Pediatric patients - Under 5 years: Zinc 100 μg per kg of body weight per day Copper 20 μg per kg of body weight per day Manganese 2 to 10 μg per kg of body weight per day Chromium 0.14 to 0.20 μg per kg of body weight per day Selenium 3 μg per kg of body weight per day.

This medication contains benzyl alcohol, and administration to neonates or premature infants can cause life-threatening respiratory problems, so it should not be used. Direct intravenous injection of this medication without dilution may result in phlebitis; therefore, it must always be used after dilution. It possesses hypo-osmotic solution characteristics and should not be used alone but must be mixed with other solutions for administration. If any toxic symptoms appear during the administration of this medication, administration must be stopped immediately. Aluminum components included in the non-oral nutritional solution may cause toxicity when administered for an extended period in patients with renal impairment, especially in premature infants, and caution is recommended. Before administration, the physician should accurately assess the patient's condition and the amount of required trace elements, and frequently check the blood trace element concentrations to adjust the dosage. In patients with renal failure, zinc excretion is difficult, which may lead to accumulation of zinc in the body, so caution is needed. In patients with biliary obstruction, copper and manganese excretion is difficult, increasing the risk of accumulation of these components in the body. In diabetic patients, chromium may affect blood sugar control, so the diabetic treatment status must be monitored and controlled. Patients with impaired kidney or gastrointestinal function may have difficulty excreting selenium, requiring dosage adjustments, and in cases of transfusion, the effects of transfusion must be considered. The safety of this medication during pregnancy has not been established, so it must be administered cautiously to pregnant women or women of childbearing potential and should only be used when the therapeutic benefits outweigh the risks. In cases of overdose, toxic symptoms related to trace elements such as zinc, copper, chromium, and selenium may appear; therefore, the dosage must be strictly adhered to, and immediate action is required if abnormal symptoms occur. This medication should be used according to a doctor’s prescription, and when added to non-oral nutritional solutions, sterile conditions must be maintained and the solution must be checked for discoloration or any unusual particles. During storage, keep in a dry place at room temperature and out of the reach of children for safety. Transferring to another container may cause deterioration of quality or accidents; therefore, it is safer to store in the original container.

Serious side effects

• Hypotension
• pulmonary edema
• jaundice
• decreased urine output
• coma

Mild side effects

• Hyperhidrosis
• decreased consciousness
• blurred vision
• tachycardia
• significant hypothermia
• hyperamylasemia
• diarrhea
• vomiting
• lethargy
• behavioral changes

This medication should be stored in a sealed container to prevent the ingress of air or moisture. The storage temperature should preferably be maintained between 15 to 30 degrees Celsius at room temperature. Proper storage will help ensure the medication's efficacy.

Appearance

A colorless and transparent vial injection containing a colorless, transparent liquid that is odorless, colorless, or light blue.

Package unit

10mL × 10 vials